title: Production and characterization of a humanized single-chain antibody against human integrin alphav beta3 protein.
abstract: Anti-angiogenesis therapy is an emerging strategy for cancer treatment. This therapy has many advantages over existing treatments, such as fewer side effects, fewer resistance problems, and a broader tumor type spectrum. Integrin αvβ3 is a heterodimeric transmembrane glycoprotein that has been demonstrated to play a key role in tumor angiogenesis and metastasis. We have used a phage antibody display to humanize a mouse monoclonal antibody (mAb E10) against human integrin αvβ3 with a predetermined CDR3 gene. Three human phage antibodies were developed. Analysis of the humanized phage antibodies by phage ELISA revealed that the antibodies retained high antigen-binding activity and detected the same epitope as the parent mAb E10. A humanized single chain Fv (scFv) antibody was expressed in Escherichia coli in a soluble form. Analysis of the purified scFv indicated that it has the same specificity and affinity as the original mAb. Cell viability assays and xenograft model results suggested that the humanized scFv possesses anti-tumor growth activity in vitro and in vivo. This successful production of a humanized scFv with the ability to inhibit αvβ3-mediated cancer cell growth may provide a novel candidate for integrin αvβ3-targeted therapy.
authors: State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China.
authors: Dabin
authors: D
authors: Liu
authors: Chen
authors: C
authors: Wang
authors: Cun
authors: C
authors: Li
authors: Xin
authors: X
authors: Zhang
authors: Baozhong
authors: B
authors: Zhang
authors: Zhiqiang
authors: Z
authors: Mi
authors: Xiaoping
authors: X
authors: An
authors: Yigang
authors: Y
authors: Tong
references: Int J Cancer. 2010 Aug 1;127(3):598-611
references: 19937796
references: Cancer. 2001 Sep 1;92(5):1347-8
references: 11571751
references: Curr Opin Cell Biol. 2008 Oct;20(5):514-9
references: 18638550
references: Mol Imaging Biol. 2011 Feb;13(1):112-20
references: 20383594
references: Clin Cancer Res. 2000 Aug;6(8):3056-61
references: 10955784
references: J Mol Biol. 2008 Oct 3;382(2):385-401
references: 18656482
references: Gene Ther. 2006 Jan;13(1):88-94
references: 16107860
references: J Immunol Methods. 2002 May 1;263(1-2):123-32
references: 12009209
references: Cancer Res. 2003 May 1;63(9):2079-87
references: 12727823
references: J Biol Chem. 2010 Mar 19;285(12):9054-66
references: 20056614
references: J Neurooncol. 2000 Oct-Nov;50(1-2):63-70
references: 11245282
references: Cell. 1994 Dec 30;79(7):1157-64
references: 7528107
references: Methods Mol Med. 2004;94:239-54
references: 14959834
references: Ophthalmol Clin North Am. 2006 Sep;19(3):361-72
references: 16935211
references: Proc Natl Acad Sci U S A. 1987 Sep;84(18):6471-5
references: 2442758
references: Graefes Arch Clin Exp Ophthalmol. 2008 Jan;246(1):81-7
references: 17674014
references: Anal Biochem. 1976 May 7;72:248-54
references: 942051
references: Nature. 1998 Jan 29;391(6666):450
references: 9461211
references: Appl Microbiol Biotechnol. 2010 Apr;86(4):1067-75
references: 20012277
references: FASEB J. 2002 Dec;16(14):2000-2
references: 12397091
references: J Clin Invest. 1999 Dec;104(11):1497-501
references: 10587512
references: Nat Rev Cancer. 2008 Aug;8(8):604-17
references: 18497750
references: J Biotechnol. 2007 May 1;129(3):539-46
references: 17306402
references: Nat Protoc. 2007;2(12):3278-84
references: 18079728
references: Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8910-5
references: 9671778
references: Neoplasia. 2008 Nov;10(11):1259-67
references: 18953435
references: Biochemistry. 1991 Oct 22;30(42):10117-25
references: 1931943
references: Clin Exp Pharmacol Physiol. 2006 May-Jun;33(5-6):482-8
references: 16700883
references: Curr Opin Biotechnol. 1999 Dec;10(6):544-9
references: 10600694
references: Cell. 1992 Apr 3;69(1):11-25
references: 1555235
references: Anticancer Agents Med Chem. 2006 Sep;6(5):407-28
references: 17017851
references: J Clin Oncol. 2007 May 1;25(13):1651-7
references: 17470857